Cytosorbents

Cytosorbents FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cytosorbents (CTSO) as of Oct 26, 2026 is 152.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 71.01 % — a change of 115.43% (higher).

FCF Conversion

152.98 %

YoY

115.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cytosorbents is 2025 152.98 % . FCF Conversion Rate (FCF/EBITDA) of Cytosorbents was 2024 71.01 % . It decreases by 115.43% higher compared to the previous year.

The Cytosorbents FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
71.81 USD
Jan 1, 2019
94.88 USD
Jan 1, 2020
93.01 USD
Jan 1, 2021
74.46 USD
Jan 1, 2022
105.72 USD
Jan 1, 2023
77.24 USD
Jan 1, 2024
71.01 USD
Jan 1, 2025
152.98 USD
The Cytosorbents FCF Conversion history
YEARFCF ConversionYoY
152.98 %+115.43%
71.01 %-8.07%
77.24 %-26.94%
105.72 %+41.98%
74.46 %-19.95%
93.01 %-1.96%
94.88 %+32.12%
71.81 %-25.35%
96.19 %+56.75%
61.37 %-48.30%
118.70 %+57.42%
75.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytosorbents Stock analysis

What does Cytosorbents do? Cytosorbents Corp is a US-American company specialized in the development of medical technologies for the treatment of life-threatening diseases and injuries. It was founded in 1997 by Dr. Phillip Chan. Originally, Cytosorbents specialized in the development of therapeutics for cancer therapy. After several development phases and a realignment of the company, they eventually focused on developing medical products for intensive care medicine. The business model of Cytosorbents is based on the development and marketing of blood purification systems that remove harmful substances and toxins from the blood. This can treat life-threatening diseases and complications such as sepsis, organ failure, or severe burns. An important product of Cytosorbents is the Cytosorb system, which consists of an extracorporeal blood purification device. The system is used to attenuate disease-related inflammatory reactions and remove harmful substances from the blood. This is intended to prevent complications and improve the survival of patients. Cytosorbents offers the Cytosorb system, among other things, for use in intensive and emergency medicine. It is used, among other things, to treat sepsis, which can lead to life-threatening organ failure. It is also used to treat severe burns, to rid the blood of toxic substances and inflammatory mediators, and thus accelerate the healing process. In addition to the Cytosorb system, the company also offers other medical products such as the HemoDefend plasma exchanger. This system is used to purify blood plasma from harmful substances while retaining the beneficial components in the plasma. It is used, among other things, to treat patients in need of a blood transfusion. Cytosorbents has experienced significant expansion in recent years. The company has established subsidiaries in Europe, Asia, and the Middle East and works closely with major hospitals and medical facilities. Additionally, the company has formed several partnerships with leading medical technology companies to expand the use of its technology in other areas. In summary, Cytosorbents is an innovative company specializing in the development of medical devices for the treatment of life-threatening diseases. The company has expanded significantly in recent years and collaborates with renowned hospitals and medical facilities. In the future, Cytosorbents will continue to refine and improve its technologies to help even more patients. Cytosorbents is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytosorbents stock

FCF Conversion Rate (FCF/EBITDA) of Cytosorbents is 152.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cytosorbents changed from 71.01 % to 152.98 %, representing a 115.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cytosorbents since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cytosorbents with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cytosorbents

All Key Metrics — Cytosorbents